HNN3.0
Register
Register
Register

Antion Biosciences

Company (SME)

antionbio.com/Geneva, Switzerland
3 profile visits

About

Antion's proprietary multiplex engineering platform is modular by design and exceptionally versatile. While most developers are able to efficiently deliver one or more genes to target cells, few are able to simultaneously remove the expression of other genes. Antion’s platform enables a seamless integration of both the co-expression and silencing of multiple genes from a single gene construct. Since this approach relies on single gene delivery step, we are able to manufacture multiplex engineered cells with unprecedented safety and efficiency when compared to other top-tier genome engineering technologies. Beyond this multiplex capability, our technology also offers the unique feature of being able to tune-down expression of molecules to desired levels. In certain cases, we have demonstrated that functional silencing to within a specified range, rather than complete knockout of a gene, can be more beneficial to the performance of therapeutic cells.

Representatives

Scientist

Antion Biosciences

Marketplace (1)

  • Project cooperation

    Antion Biosciences: Gene Engineering Solutions

    Antion’s modular platform enables precise multiplex gene silencing with synthetic miRNA and co-expression in one safe delivery step.

    • Partner seeks Consortium/Coordinator
    • DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-15: Scaling up innovation in cardiovascular health
    • DESTINATION 4: HORIZON-HLTH-2026-01-CARE-03: Identifying and addressing low-value care in health and care systems
    • DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-04: Development of novel vaccines for viral pathogens with epidemic potential
    • DESTINATION 6: HORIZON-HLTH-2026-01-IND-03: Regulatory science to support translational development of patient-centred health technologies
    • DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-03: Integrating New Approach Methodologies (NAMs) to advance biomedical research and regulatory testing
    • DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-03: Advancing research on the prevention, diagnosis, and management of post-infection long-term conditions
    • DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-05: Pilot actions for follow-on funding: Leveraging EU-funded collaborative research in regenerative medicine
    • DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-07: Establishing a European network of Centres of Excellence (CoEs) for Advanced Therapies Medicinal Products (ATMPs)
    • DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-11: Understanding of sex and/or gender-specific mechanisms of cardiovascular diseases: determinants, risk factors and pathways
    • DESTINATION 4: HORIZON-HLTH-2026-01-CARE-01: Public procurement of innovative solutions for improving citizens' access to healthcare through integrated or personalised approaches
    • DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-02: Innovative interventions to prevent the harmful effects of using digital technologies on the mental health of children and young adults
    • DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-06: Support to European Research Area (ERA) action on accelerating New Approach Methodologies (NAMs) to advance biomedical research and testing of medicinal products and medical devices
    • DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-09: Multisectoral approach to tackle chronic non-communicable diseases: implementation research maximising collaboration and coordination with sectors and in settings beyond the healthcare system (GACD)
    Author

    Scientist at Antion Biosciences

    Plan-Les-Ouates, Switzerland